CC-8490

DRUG2 trials

Sponsors

National Cancer Institute (NCI), Celgene Corporation

Conditions

Brain and Central Nervous System TumorsGlioblastomaMalignant Gliomas

Phase 1

CC-8490 in Treating Patients With Recurrent or Refractory High-Grade Gliomas

CompletedNCT00074243

National Cancer Institute (NCI)Brain and Central Nervous System Tumors

Start: 2003-12-31Updated: 2015-04-30

Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas

CompletedNCT00074646

Celgene CorporationGlioblastoma, Malignant Gliomas

Start: 2003-12-31End: 2005-06-30Target: 36Updated: 2007-01-04